Abbott Laboratories (ABT)
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?
ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.
Abbott Stock Could Be On The Verge Of A Breakout - Here's What Smart Money Sees
Abbott Laboratories is undervalued by the market, despite its strong fundamentals and strategic moves in high-growth areas like diabetes care and weight-loss treatments. The company boasts a high net income margin of 31.95% and generates over $8.5 billion in cash from operations, providing significant flexibility. Abbott's FreeStyle Libre system and new Protality brand highlight its long-term growth potential in diabetes care and weight-loss treatment markets.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
2 Dependable Dividend Stocks That Can Pay You for Life
What makes an outstanding dividend stock? High yields can seem attractive to income seekers, but unless a company has a steady, reliable business, payout cuts are a real possibility no matter how juicy its dividend yield.
Strong Earnings Lift Abbott Laboratories Shares
Health care company Abbott Laboratories (ABT) increases sales, earnings around the globe.
My Best Dividend Aristocrats For March 2025
The ProShares S&P 500 Dividend Aristocrat ETF kicks off 2025 on a bright note with a gain of 2.81% in January. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 43 months of tracking these strategies, one strategy is generating a CAGR superior to NOBL.
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know
The latest trading day saw Abbott (ABT) settling at $133.17, representing a +0.79% change from its previous close.
Expanding Diabetes Business Supports ABT Stock, FX Issues Stay
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
